Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
16 avr. 2024 11h01 HE
|
Psyence Group Inc.
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health...
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
26 mars 2024 11h06 HE
|
Psyence Group Inc.
TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Further to the announcement by Psyence Group Inc ("Psyence" or the "Company") (CSE:PSYG) of its plans for the strategic restructuring of its non-clinical...
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
12 mars 2024 11h15 HE
|
Psyence Group Inc.
NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in...
Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division
11 mars 2024 07h00 HE
|
Psyence Group Inc.
TORONTO, March 11, 2024 (GLOBE NEWSWIRE) -- Further to the announcement by Psyence Group Inc ("Psyence Group" or the "Company") (CSE:PSYG) of the closing (the "Closing") of the business combination...
Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
25 janv. 2024 18h03 HE
|
Psyence Group Inc.
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group"), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health...
Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
25 janv. 2024 17h17 HE
|
Psyence Group Inc.
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (“Psyence Biomed”) is excited to announce the completion of its merger (the “Business Combination”) with Newcourt Acquisition Corp...
Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination
16 janv. 2024 07h54 HE
|
Psyence Group Inc.
TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in...
Psyence Group Announces Resignation of Board Member
20 nov. 2023 14h38 HE
|
Psyence Group Inc.
TORONTO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG) (“Psyence” or the “Company”), a clinical-stage life science biotechnology company pioneering the use of nature-derived...
Psyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp
15 nov. 2023 12h18 HE
|
Psyence Group Inc.
TORONTO, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and...
Psyence Production Expands Capability
30 oct. 2023 11h09 HE
|
Psyence Group Inc.
TORONTO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and...